AUTHORS
Livio Pagano, MD, Alessandra Sperotto, MD2, Elisabetta Todisco, MD3, Roberto M. Lemoli4, Massimo Breccia, MD5, Alessandro Putelli6, Antonino Mule', MD7, Michela Rondoni, MD8, Saemi Park, PhD9, Giovanna Dinelli, PhD10, Rafaella Gentilella, MD11, Francesco Buccisano, MD, PhD12, Adriano Venditti, MD13
AFFILIATIONS
1 Department of Laboratory and Hematological Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
2 Onco Hematology, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Castelfranco Veneto, Italy
3 Busto Arsizio Hospital, ASST-Valle Olona, Hematology Department and Stem cell Transplantation, ASST-Valle Olona, Italy
4 Clinic of Hematology AOM IRCCS San Martino, Genoa, Italy, Department of Internal Medicine (DiMI), University of Genoa, Italy, Genoa, Italy
5 Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy
6 University of Milano Bicocca and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXII, Bergamo, Italy
7 Onco-Hematology Unit, Ospedale Villa Sofia Cervello, Palermo, Italy
8 Hematology Unit & Metropolitan Transplant Network, Ravenna, AUSL Romagna, Ravenna, Italy
9 Jazz Pharmaceuticals plc, Dublin, Ireland
10 Jazz Pharmaceuticals plc, Dublin, Ireland
11 Jazz Pharmaceuticals plc, Dublin, Ireland
12 Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy
13 Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy
ABSTRACT
CPX-351, a dual-drug liposomal formulation of daunorubicin and cytarabine, improved outcomes vs 7+3 chemotherapy in the pivotal phase 3 trial in adults with newly diagnosed (ND) therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Although retrospective studies have supported its effectiveness and safety, prospective real-world data are lacking. The VYxeoS liposomal® Italian Observational study iN the real practice (VYSION; ClinicalTrials.gov identifier: NCT06143839) is the first prospective, non-interventional study of CPX-351, evaluating outcomes following its use in routine clinical practice in Italy. Data was collected directly during patient treatment, allowing for more complete and standardized capture of clinical outcomes than is typically possible in retrospective studies, enhancing the clinical relevance of findings. Here, we present effectiveness and safety data from VYSION.
VYSION was conducted in adult patients with ND t-AML or AML-MRC, per the 2016 WHO classification, considered eligible for intensive chemotherapy in the treating physician’s opinion. In this analysis we assessed the percentage of patients who achieved complete response (CR)/CR with incomplete hematologic recovery (CRi)/CR with partial hematologic recovery (CRh) after CPX-351 induction and at the end of treatment, according to the 2022 European LeukemiaNet (ELN) response criteria. End of treatment was defined as the last response evaluation after the last treatment cycle. Other outcomes included overall survival (OS) from CPX-351 treatment initiation date; hematopoietic stem cell transplantation (HSCT) rate; OS landmarked from HSCT date; and safety.
Overall, 105 patients (t-AML, n=22; AML-MRC, n=83) received ≥1 induction of CPX-351 (1 cycle, n=105; 2 cycles, n=17) and 51 patients received consolidation (1 cycle, n=51; 2 cycles, n=21). Median age at AML diagnosis was 68 years (interquartile range [IQR] 61-71); 22 (21%) patients were aged <60 years. Of patients with available cytogenetic data, 57/102 (56%) had an abnormal karyotype. Of patients with available genetic data 34/96 (35%) had at least 1 mutation among ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2; 20/94 (21%) had a TP53 mutation; and 68/103 (66%) were classified as adverse-risk per ELN 2022 risk score. Of those with AML-MRC, 33 (40%) had history of myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasms, 28 (34%) had an MDS-related cytogenetic abnormality, and 35 (43%) had multilineage dysplasia.
CR/CRi/CRh after CPX-351 induction (1 or 2 cycles) was achieved by 60% of 96 evaluable patients (t-AML, 67%; AML-MRC, 59%). CR/CRi/CRh at the end of CPX-351 treatment was confirmed in 52% of 99 evaluable patients (t-AML, 38%; AML-MRC, 55%). No assessment data were available for 6 patients who died before the scheduled assessment. After a median follow-up of 8.9 (IQR 4.5-14.0) months, median OS from CPX-351 treatment initiation was 14.3 (95% CI: 11.3, NE) months. Thirty- and 60-day mortality rates were 3.8% and 5.7%, respectively. HSCT was performed in 44/105 (42%) patients. Median time to HSCT since the last dose was 76.5 (IQR 58.5-96.0) days. Among 38 evaluable patients, median time to engraftment was 16.5 (IQR 15-19) days. Graft versus host disease occurred in 14/44 (32%) patients. Patients who underwent HSCT had a median OS, landmarked from HSCT date, of 14.6 (95% CI: 10.2, NE) months, and 10/44 (23%) non-relapse mortality events were observed. Median OS from CPX-351 treatment initiation was NE (95% CI: 17.1-NE) in patients who underwent HSCT, compared with 8.9 months (95% CI: 6.2-12.7) in non-HSCT patients. Adverse events (AEs) occurred in 85 (81%) patients; 31 (30%) had treatment-related AEs and 14 (13%) experienced treatment-related serious AEs. AEs of special interest occurred in 71 (68%) patients, including febrile neutropenia in 32/105 (30%) patients, and infections in 26/105 (25%), including sepsis and septic shock (10% each). Gastrointestinal toxicity and cardiac events were reported in 12% and 7% of patients, respectively. Additional efficacy data will be presented at the ASH Annual Meeting.
These results provide valuable insights into the effectiveness and safety of CPX-351 for the treatment of t-AML and AML-MRC in routine clinical practice in Italy, consistent with the pivotal trial and published real-word data. These results support the continued use of CPX-351 as the standard of care for ND t-AML or AML-MRC.
DISCLOSURES
Francesco Buccisano, MD, PhD: Novartis - Consultancy (Includes expert testimony); Astellas Pharma - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Menarini-Stemline Therapeutics - Consultancy (Includes expert testimony)